title: [Glucocorticoide therapy in premature infants: French practices in 2006].
abstract: OBJECTIVE
  In 1999, 80% of French neonatal centers used corticosteroids, mainly betamethasone (BMT), to prevent or treat bronchopulmonary dysplasia (BPD) [Lee SK, McMillan DD, Ohlson A, et al. Variations in practice and outcomes in the canadian NICU Network 1996-1997. Pediatrics 2000;106:1070-9]. As many data suggested a low risk-benefit ratio, an updated assessment of this use was necessary [Desnoulez L, Empana J, Anceschi M, et al. Prise en charge de l'immaturité pulmonaire en néonatologie : enquête sur les pratiques européennes. Arch Pediatr 2005;12:4-9; Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (less than 96h) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003:CD001146; Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004;350:1304-13; Lin YJ, LKin CH, Wu JM, et al. The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a 2-year follow-up study. Acta Paediatr 2005;94:310-16].
  
  
  METHODS
  Questionnaires addressing the use of and indications for corticosteroids were sent to all French neonatal centers.
  
  
  RESULTS
  The study was conducted over 5 months (July to November 2006). Of 202 questionnaires sent out, 186 (92%) were completed. Of these 186 centers, 147 (79%) had a standard protocol for corticosteroid use, covering systemic and inhaled steroids (76 units), only systemic steroid therapy (30 units) and only inhaled steroids (41 units). Systemic corticosteroids were used in 106 centers for hemodynamic purposes in 42 cases (40%), prevention of BPD in 1 case (1%), early treatment of BPD (day 4 to day 21) in 23 cases (22%) and late treatment of BPD (after day 21) in 74 cases (70%). Hemisuccinate hydrocortisone (HSHC) was the only corticoid used for hemodynamic failure. The steroid used for early treatment of BPD was BMT (21 out of 23). The duration of treatment was less than 4 days in 10 centers (43%). The steroid most often used for late treatment was BMT (67 out of 74). The duration of treatment was less than 4 days in 29 centers, between 4 and 8 days in 22 centers, and longer than 8 days in 26 centers. Among 117 centers administering corticosteroids by inhalation, 74% used budesonide. Use of corticosteroids was higher in teaching hospitals (86%) than in others (49%), likely due to the immaturity of the neonates hospitalized in these centers.
  
  
  CONCLUSIONS
  We showed a still frequent use of corticosteroids in preterm infants in France but only after the fourth day of life to treat BPD and not as a prevention therapy. We also found a marginal use of DXM in accordance with both short-term and long-term adverse side effects, suggesting an unbalanced risk-benefit ratio even though it has a beneficial effect on respiratory status. Our findings indicate the need for national recommendations and trials to assess oral BMT treatment in premature neonates with BPD.
authors.affiliation: Service de pharmacologie clinique, centre régional de pharmacovigilance et d'information sur médicament, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France. autret-leca@med.univ-tours.fr
authors.forename: E
authors.initials: E
authors.lastname: Autret-Leca
authors.forename: S
authors.initials: S
authors.lastname: Bauer
authors.forename: C
authors.initials: C
authors.lastname: Alberti
authors.forename: A-P
authors.initials: AP
authors.lastname: Jonville-Béra
authors.forename: Y
authors.initials: Y
authors.lastname: Aujard
authors.forename: L
authors.initials: L
authors.lastname: Bensouda-Grimaldi
authors.forename: O
authors.initials: O
authors.lastname: Baud
mesh_terms: D000280:Administration, Inhalation; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D001623:Betamethasone / Q000009:adverse effects / Q000627:therapeutic use; D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy* / Q000517:prevention & control; D019819:Budesonide / Q000009:adverse effects / Q000627:therapeutic use; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D005602:France; D005865:Gestational Age; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006854:Hydrocortisone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D008297:Male; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*; D018570:Risk Assessment; D011795:Surveys and Questionnaires
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D019819:Budesonide; D003907:Dexamethasone; D001623:Betamethasone; D011239:Prednisolone; C007133:hydrocortisone hemisuccinate; D006854:Hydrocortisone